Tags |
|
|
Links |
|
|
Advice You - Employee Stock Ownership Plan (ESOP) Valuation Issues Q&A
ESOPs have become an effective tool in corporate finance and tax planning. Not only do they provide retirement benefits and incentives to employees but an ESOP can provide unique ways to transition company management in tax favored environments. An ESOP can even be used to increase cash flow or convert debt to a pre-tax environment.
Why do we need to engage an outside party to value our ESOP shares? From a strictly
Why do we need to engage an outside party to value our ESOP shares? From a strictly
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
regulatory standpoint, a valuation of ESOP shares by an independent third party is required by the Department of Labor (DOL) and the Internal Revenue Service (IRS). The regulatory requirement stems from the practical need to insure that the value is determined by a party who does not have a personal or financial interest in the valuation result. The valuation, moreover, should be performed on behalf of the ESOP trustee since it is t
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
e duty of the trustee to insure that transactions with the ESOP are consummated at “fair market value.”
What is meant by “fair market value”? Fair Market Value (FMV) is a concept and not a price that emerges from application of some standard formula. In simple terms, FMV is the price for which property would sell under the existing market conditions for such property as established in arms-length negotiations betwe
What is meant by “fair market value”? Fair Market Value (FMV) is a concept and not a price that emerges from application of some standard formula. In simple terms, FMV is the price for which property would sell under the existing market conditions for such property as established in arms-length negotiations betwe
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
en knowledgeable and independent parties. The “market” implied in definitions of FMV encompasses all potential buyers and sellers of the property involved.
How is “fair market value” determined? There are many method used in the determination of FMV. The nature of the property being evaluated determines what methods are appropriate. For example, the FMV of a single family home is determined by the price for which
How is “fair market value” determined? There are many method used in the determination of FMV. The nature of the property being evaluated determines what methods are appropriate. For example, the FMV of a single family home is determined by the price for which
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
imilar property is selling in the area in which such property is located. The FMV of business interests that is generating earnings, however, is determined to a large degree on the basis of what a knowledgeable buyer would be willing to pay for the earnings stream considering available rates of return on relatively risk-free investments and the risks associated with the investment being appraised. Although not the only method that mi
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
ght be considered, the present value of future earnings using a risk adjusted market rate is one of the most common approaches, referred to in business valuations as Discounted Future Earnings (DFE).
Reference to the results of mathematical formulas is not the sole determinant of FMV. The judgment and experience of the valuation analyst is also a critical element since there can be many factors that can not be quantified by reference
Reference to the results of mathematical formulas is not the sole determinant of FMV. The judgment and experience of the valuation analyst is also a critical element since there can be many factors that can not be quantified by reference
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
to the underlying financial information alone.
What is meant by a “control premium”? A control premium is that amount which a buyer may be willing to pay to acquire a controlling interest in a business over and above the value of the interest based solely on the underlying financial factors. The element of control, in this case, has a value which is added to the value that can otherwise be ascribed to the assets an
What is meant by a “control premium”? A control premium is that amount which a buyer may be willing to pay to acquire a controlling interest in a business over and above the value of the interest based solely on the underlying financial factors. The element of control, in this case, has a value which is added to the value that can otherwise be ascribed to the assets an
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
d earnings of the business. The payment of a control premium in the purchase of a business does not necessarily add any value to the business.
Synergy value, unlike control, is susceptible to being measured in more concrete terms of increased financial benefits to the buyer over and above those being enjoyed by the selling parties. Examples are the prospects of increased sales of the buyer’s products to the seller’s customer base o
Synergy value, unlike control, is susceptible to being measured in more concrete terms of increased financial benefits to the buyer over and above those being enjoyed by the selling parties. Examples are the prospects of increased sales of the buyer’s products to the seller’s customer base o
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
lower overall materials costs due to volume purchase discounts, etc. Whether or not a control premium is appropriate in the purchase of shares by an ESOP must be determined on the facts in the individual case. Moreover, since the ESOP generally doesn’t control a company itself, there is much debate as to whether or not an ESOP can pay a control premium for shares purchased, even if purchasing a controlling percentage.
How d
How d
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
o ESOP valuations differ from valuations for other purposes? Because of the regulatory requirement established in the Employee Retirement & Income Security Act of 1974 (ERISA) that an ESOP pay no more than “adequate consideration” in the purchase of employer securities, ESOP valuations must support the decisions of the trustees and must also withstand review by DOL and the IRS. Valuations that are subject to being reviewed b
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
third parties, whether for ESOP or other purposes, must include considerable discussions on the methods and factors employed as well as explanatory information on the sponsoring company’s financial and operating history and the industry in which it competes.
For similar reasons, valuations supporting tax related values for gift and estate or charitable deduction purposes must also include considerable background detail so that poten
For similar reasons, valuations supporting tax related values for gift and estate or charitable deduction purposes must also include considerable background detail so that poten
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
tial third party reviewers will have a clear understanding of the process leading up to the value conclusion. In addition, ESOP regulations place various obligations on the sponsoring employer and allow for limitation of the voting rights of ESOP shares. These, and other features specific to the ESOP require special consideration in the determination of the fair market value of ESOP owned securities of privately held companies. It i
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
strongly recommended that an ESOP trustee utilize an appraiser who is knowledgeable in the design and use of ESOPs since they are extremely unique in their different applications.
What is the cost of an ESOP valuation? The fees charged for ESOP valuations vary considerably from one valuation firm to the next. There is no set industry standard or prescribed range. This is due to the wide variation in the amount of
What is the cost of an ESOP valuation? The fees charged for ESOP valuations vary considerably from one valuation firm to the next. There is no set industry standard or prescribed range. This is due to the wide variation in the amount of
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
work that may be involved between one engagement and another. As a general rule, the cost of an initial valuation for a newly formed ESOP will be higher than the subsequent annual update valuations. This is because of the amount of time and work involved in gathering and analyzing all of the financial, industry and other pertinent information for the initial report. The update, on the other hand, need only focus on changes in finan
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
ial and other factors that have occurred since the prior report.
Are there different types of ESOP valuations? Because few companies are willing to adopt an ESOP before determining whether or not the value of company stock will support management objectives, Greenstein, Rogoff, Olsen & Co., LLP offers limited valuations for feasibility purposes to reduce the initial costs of implementing an ESOP. Since this valuatio
Are there different types of ESOP valuations? Because few companies are willing to adopt an ESOP before determining whether or not the value of company stock will support management objectives, Greenstein, Rogoff, Olsen & Co., LLP offers limited valuations for feasibility purposes to reduce the initial costs of implementing an ESOP. Since this valuatio
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
n is for company management purposes, all of the time consuming company and industry background report writing can be eliminated. The company’s management is fully aware of these matters and need not pay for the privilege of reading about them in a valuation report prepared exclusively for management use only. All pertinent factors are considered in the analysis leading to the value conclusion and all requisite financial data and val
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
ation methods used for a full report are outlined in the limited report as well.
Is Greenstein, Rogoff, Olsen & Co., LLP (GROCO) considered an independent party for ESOP valuation purposes?
It is common knowledge in the valuation industry that “independence” means that the appraiser is not affiliated with nor has any present or intended future financial interest in the company for which the ESOP valuation is being pr
Is Greenstein, Rogoff, Olsen & Co., LLP (GROCO) considered an independent party for ESOP valuation purposes?
It is common knowledge in the valuation industry that “independence” means that the appraiser is not affiliated with nor has any present or intended future financial interest in the company for which the ESOP valuation is being pr
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
ovided. However, in a recent court case (Santa Monica Pictures et al v Commissioner, T.C. Memo 2005-105, May 11, 2005) the Court expressed concerns that portions of an expert’s report “have the distinct quality of advocacy.” Although this case does not involve ESOPs or an ESOP valuation, the case points out the importance that valuation conclusions be relevant, reliable and unbiased.
Although an appraiser may not have any present f
Although an appraiser may not have any present f
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
nancial interest in the company being appraised, if their firm provides ESOP installation and administration services and the decision to install an ESOP rests largely on the results of the valuation, can the appraiser in that situation truly provide an unbiased opinion of value, given their obvious financial benefit from the installation of the ESOP? GROCO does not derive income from the drafting of plan documents, plan submissions to
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
the IRS, and other activity involved in the adoption of an ESOP by the client. In addition, GROCO does not offer annual ESOP administrative services. Accordingly, we have no pecuniary interest in the client’s decision to adopt the ESOP or the continued operation of the ESOP and therefore can truly give an unbiased opinion of value in feasibility situations. Therefore, GROCO is truly an independent party for ESOP valuation purposes
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.adviceyou.org.ua/article/2629/adviceyou-Employee-Stock-Ownership-Plan-ESOP-Valuation-Issues-QA.html">Employee Stock Ownership Plan (ESOP) Valuation Issues Q&A</a>
BB link (for phorums):
[url=http://www.adviceyou.org.ua/article/2629/adviceyou-Employee-Stock-Ownership-Plan-ESOP-Valuation-Issues-QA.html]Employee Stock Ownership Plan (ESOP) Valuation Issues Q&A[/url]
Related Articles:
Bookmark it:
|